Alzheimer’s disease (AD) is the most common cause of dementia associated with a
progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the …

Alzheimer's disease (AD) is the primary cause of age-related dementia. Effective strategies
to prevent and treat AD remain elusive despite major efforts to understand its basic biology …

Deposition of amyloid β-protein (Aβ) in the brain is an early and invariant neuropathological
feature of Alzheimer’s disease (AD). The current search for anti-AD drugs is mainly focused …

… Even if these precision approaches alone are not successful in preventing AD, they may
greatly improve the likelihood of amyloid- or tau-specific therapies to reach their endpoints by …

… field of dementia is focused on Alzheimer’s dementia (AD), this review will focus on
pharmacological interventions in AD. Most disease-modifying therapies are based on the amyloid …

… capabilities of individuals afflicted with Alzheimer’s disease. In the near future, this research
will provide the answer to the cure and possible early prevention of Alzheimer’s disease. …

… , and the projected increase in prevalence of Alzheimer’s disease (AD) over the next 50
years makes a strong case for developing therapies that can prevent or delay the onset of AD. …

Alzheimer's disease (AD), the leading cause of dementia, has reached epidemic proportions,
with major social, medical and economical burdens. With no currently available curative …

… and chronic diseases are more and more common. For several of these pathologies, only
few drugs have been available for therapies over the years. Alzheimer's disease (AD), for …

… Alzheimer’s disease (AD) clinical trials, focused on disease modifying drugs and conducted
… design aimed at improving our ability to identify novel therapies for this devastating disease. …